Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine for Prevention of Post-Operative Atrial Fibrillation
NCT01352416Phase 3Terminated
- Sponsor
- Corewell Health
- Start
- Sep 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranolazine in Atrial fibrillation (AFib) (4 arms), sponsored by Corewell Health. Primary endpoint: Freedom From Any Episode of Post Operative Atrial Fibrillation Longer Than 6 Hours Duration Occurring During the Study Period at 14 days. Started Sep 2010; status: terminated.
02
Drugs
ranolazine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01352416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01352416.